Published in Biochem Biophys Res Commun on April 15, 1992
Localization of the human alpha-globin structural gene to chromosome 16 in somatic cell hybrids by molecular hybridization assay. Cell (1977) 4.34
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med (1991) 3.52
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res (2000) 2.86
MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene (2007) 2.79
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood (2001) 2.71
Catalase: Physical and chemical properties, mechanism of catalysis, and physiological role. Physiol Rev (1970) 2.69
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia (2002) 2.68
Chromosomal localization of human beta globin gene on human chromosome 11 in somatic cell hybrids. Proc Natl Acad Sci U S A (1978) 2.65
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther (2008) 2.50
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol (1999) 2.38
Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med (1996) 2.29
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med (1984) 2.26
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest (2001) 2.21
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood (2000) 2.11
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med (1994) 2.09
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med (1993) 2.09
High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood (1992) 2.07
Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood (1992) 2.05
Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. Proc Natl Acad Sci U S A (1972) 2.01
Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science (1990) 1.90
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia (2008) 1.84
Human alpha-globin gene expression following chromosomal dependent gene transfer into mouse erythroleukemia cells. Cell (1978) 1.84
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Influenza among hospitalized adults with leukemia. Clin Infect Dis (1997) 1.68
Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst (1997) 1.63
The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol (2007) 1.62
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia (2002) 1.62
Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst (1990) 1.61
Cytokine-regulated expression of survivin in myeloid leukemia. Blood (2001) 1.56
Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood (1991) 1.56
MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia (2008) 1.53
The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy (2008) 1.52
Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur J Cancer (1992) 1.51
A temperature-sensitive mutant of human p53. EMBO J (1994) 1.51
The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia (2008) 1.48
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia (2005) 1.44
The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood (1995) 1.44
Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med (1981) 1.43
Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood (1994) 1.41
Chronic myelogenous leukemia: a concise update. Blood (1993) 1.40
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia (2003) 1.39
Apoptosis. Molecules and mechanisms. Adv Exp Med Biol (1999) 1.30
The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia (2005) 1.30
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia (2011) 1.30
Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene (1989) 1.30
Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood (1980) 1.29
Correlation of DNA distribution abnormalities with cytogenetic findings in human adult leukemia and lymphoma. Cancer Res (1977) 1.27
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia (2004) 1.24
Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis (2006) 1.22
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res (2000) 1.22
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood (1998) 1.22
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood (1995) 1.18
Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis (1995) 1.17
Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res (1996) 1.17
Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene (1993) 1.16
Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia (2003) 1.16
A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol (1988) 1.13
Expression of human alpha-globin genes in hybrid mouse erythroleukaemia cells depends on differentiated state of human donor cell. Nature (1980) 1.13
Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol (1999) 1.11
Changes of cellular markers during differentiation of HL-60 promyelocytes to macrophages as induced by T lymphocyte conditioned medium. Leuk Res (1981) 1.11
The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene (2011) 1.11
Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res (1999) 1.11
Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood (1996) 1.11
Activation of phenotypic expression of human globin genes from nonerythroid cells by chromosome-dependent transfer to tetraploid mouse erythroleukemia cells. Proc Natl Acad Sci U S A (1979) 1.10
Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol (1997) 1.10
Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood (1997) 1.09
Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia (2009) 1.09
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ (2007) 1.08
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res (1999) 1.08
Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood (1999) 1.07
Characterization of hematologic malignancies by flow cytometry. Blood Cells (1980) 1.04
Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry (1993) 1.04
Infra-His bundle origin of bidirectional tachycardia. Circulation (1973) 1.04
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood (1995) 1.03
Hemoglobin synthesis in somatic cell hybrids: coexpression of mouse with human or chinese hamster globin genes in interspecific somatic cell hybrids of mouse erythroleukemia cells. Proc Natl Acad Sci U S A (1975) 1.03
Hyperphosphorylation of p53 induced by okadaic acid attenuates its transcriptional activation function. Cancer Res (1994) 1.03
Hemoglobin synthesis in somatic cell hybrids: globin gene expression in hybrids between mouse erythroleukemia and human marrow cells or fibroblasts. Proc Natl Acad Sci U S A (1975) 1.03
Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia (2011) 1.03
hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther (2002) 1.02
A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood (1996) 1.02
[Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations]. Nuklearmedizin (2009) 1.02
Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Leukemia (2009) 1.01
Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene (1992) 1.01
Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia (2011) 1.01
Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha. Cancer Res (1994) 1.01
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol (1995) 1.00
Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Ther (2007) 1.00